Fulcrum Therapeutics, Inc.

8-K · fulc-20260601.htm iXBRL

0001680581 2026-06-01 2026-06-01

  
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
 FORM 8-K
  
 CURRENT REPORT
 Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): June 01, 2026

  
  
 Fulcrum Therapeutics, Inc.
 (Exact name of registrant as specified in its charter)
  
  

 Delaware

 001-38978

 47-4839948

 (State or other jurisdiction
of incorporation)

 (Commission File Number)

 (IRS Employer
Identification No.)

  

  

  

  

  

 26 Landsdowne Street

  

 Cambridge , Massachusetts

  

 02139

 (Address of principal executive offices)

  

 (Zip Code)

  

 Registrant’s telephone number, including area code: (617) 651-8851

  

 N/A

 (Former name or former address, if changed since last report)
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

 Trading
Symbol(s)

  

Name of each exchange on which registered

 Common stock, par value $0.001 per share

  

 FULC

  

 Nasdaq Global Market

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 Emerging growth company ☐
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  

 Item 8.01 Other Events .
 On June 1, 2026, Fulcrum Therapeutics, Inc., or the Company, announced the discontinuation of its pociredir program for the treatment of sickle cell disease, or SCD, and the initiation of a comprehensive review of strategic alternatives intended to maximize stockholder value.
 A copy of the press release announcing these matters is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 Item 9.01 Financial Statements and Exhibits.
 (d) Exhibits
  

 99.1

 Press release, dated June 1, 2026

 104

 Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

  

 SIGNATURES
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  

  

 FULCRUM THERAPEUTICS, INC.

  

  

  

  

 Date:

 June 1, 2026

 By:

 /s/ Alex C. Sapir

  

  

  

 Name: Alex C. Sapir
Title: President and Chief Executive Officer